{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:19:42Z","timestamp":1761128382585,"version":"3.32.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1136\/ard.2005.042416","type":"journal-article","created":{"date-parts":[[2005,10,26]],"date-time":"2005-10-26T07:03:39Z","timestamp":1130310219000},"page":"iv31-iv36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"S4","title":["Current state of tumour necrosis factor \u03b1 blockade in Wegener's granulomatosis"],"prefix":"10.1016","volume":"64","author":[{"given":"C","family":"Mukhtyar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Luqmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2005.042416_bib1","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.042416_bib2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/thx.42.12.918","article-title":"On generalised septic vessel diseases. By Friedrich Wegener, 1937 [translation]","volume":"42","author":"Wegener","year":"1987","journal-title":"Thorax"},{"key":"10.1136\/ard.2005.042416_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","article-title":"Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years","volume":"98","author":"Fauci","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2005.042416_bib4","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0002-9343(79)90634-X","article-title":"Immunosuppressive and corticosteroid therapy of polyarteritis nodosa","volume":"67","author":"Leib","year":"1979","journal-title":"Am J Med"},{"key":"10.1136\/ard.2005.042416_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.1780310402","article-title":"Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis","volume":"31","author":"Stillwell","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.042416_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2005.042416_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.042416_bib8","first-page":"779","article-title":"Relapses in patients with a systemic vasculitis","volume":"86","author":"Gordon","year":"1993","journal-title":"Q J Med"},{"key":"10.1136\/ard.2005.042416_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remissions in \u201cnon-renal\u201d ANCA-associated vasculitis","author":"de Groot","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.042416_bib10","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2004-01-0267","article-title":"Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo","volume":"104","author":"Pfister","year":"2004","journal-title":"Blood"},{"key":"10.1136\/ard.2005.042416_bib11","first-page":"131","article-title":"Systemic injection of products of activated neutrophils and H2O2 in myeloperoxidase-immunized rats leads to necrotizing vasculitis in the lungs and gut","volume":"151","author":"Heeringa","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1136\/ard.2005.042416_bib12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1136\/ard.2005.042416_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2249.1990.tb03336.x","article-title":"Enhanced expression of the tumour necrosis factor\/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis","volume":"81","author":"Deguchi","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"10.1136\/ard.2005.042416_bib14","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.4049\/jimmunol.160.7.3602","article-title":"Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10","volume":"160","author":"L\u00f9dv\u00edksson","year":"1998","journal-title":"J Immunol"},{"key":"10.1136\/ard.2005.042416_bib15","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V84.12.4008.bloodjournal84124008","article-title":"Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes","volume":"84","author":"Trinchieri","year":"1994","journal-title":"Blood"},{"key":"10.1136\/ard.2005.042416_bib16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2249.1994.tb06518.x","article-title":"Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo","volume":"95","author":"Csernok","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1136\/ard.2005.042416_bib17","first-page":"2406","article-title":"De novo synthesis of proteinase 3 by cytokine primed circulating human polymorphonuclear neutrophils and mononuclear cells","volume":"27","author":"Zhou","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2005.042416_bib18","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/01.ASN.0000113241.98702.77","article-title":"Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18","volume":"15","author":"Hewins","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1136\/ard.2005.042416_bib19","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1084\/jem.184.6.2231","article-title":"Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming","volume":"184","author":"Gilligan","year":"1996","journal-title":"J Exp Med"},{"key":"10.1136\/ard.2005.042416_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1046\/j.1365-2249.2000.01410.x","article-title":"Opsonization of apoptotic neutrophils by anti-neutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumour necrosis factor-alpha (TNF-alpha)","volume":"122","author":"Moosig","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1136\/ard.2005.042416_bib21","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/ki.1993.98","article-title":"In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis","volume":"43","author":"Noronha","year":"1993","journal-title":"Kidney Int"},{"key":"10.1136\/ard.2005.042416_bib22","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/S0002-9440(10)61118-2","article-title":"Peripheral blood and granuloma CD4(+)CD28(\u2212) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis","volume":"160","author":"Komocsi","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1136\/ard.2005.042416_bib23","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F","article-title":"Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.042416_bib24","first-page":"671","article-title":"Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"Q J Med"},{"key":"10.1136\/ard.2005.042416_bib25","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","article-title":"A Disease-Specific Activity Index for Wegener's Granulomatosis: Modification of the Birmingham Vasculitis Activity Score","volume":"44","author":"Stone","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.042416_bib26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","author":"Wegener's Granulomatosis Etanercept Trial (WGET) Research Group","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.042416_bib27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/1529-0131(199904)42:4<751::AID-ANR19>3.0.CO;2-D","article-title":"Wegener's granulomatosis associated with renal cell carcinoma","volume":"42","author":"Tatsis","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.042416_bib28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ijc.10444","article-title":"Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis","volume":"100","author":"Knight","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1136\/ard.2005.042416_bib29","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/rheumatology\/keh374","article-title":"Malignancy is increased in ANCA-associated vasculitis","volume":"43","author":"Pankhurst","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2005.042416_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.canlet.2004.07.027","article-title":"Tumor necrosis factor alpha promotes invasiveness of cholangiocarcinoma cells via its receptor, TNFR2","volume":"219","author":"Tanimura","year":"2005","journal-title":"Cancer Lett"},{"key":"10.1136\/ard.2005.042416_bib31","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.042416_bib32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/ard.61.6.559","article-title":"Safety and efficacy of TNFalpha blockade in relapsing vasculitis","volume":"61","author":"Booth","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2005.042416_bib33","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","article-title":"Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients","volume":"41","author":"Bartolucci","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2005.042416_bib34","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","article-title":"Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis","volume":"41","author":"Lamprecht","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2005.042416_bib35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","article-title":"Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis","volume":"15","author":"Booth","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1136\/ard.2005.042416_bib36","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1136\/ard.2005.042416_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.2004.024182","article-title":"Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha","volume":"64","author":"Eriksson","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2005.042416_bib38","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.042416_bib39","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/art.11033","article-title":"Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis","volume":"48","author":"Carlson","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.042416_bib40","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1046\/j.1365-2133.2002.4653_4.x","article-title":"Dermatological complications of etanercept therapy for rheumatoid arthritis","volume":"146","author":"Misery","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard.2005.042416_bib41","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","article-title":"Drug-induced systemic lupus erythematosus associated with etanercept therapy","volume":"359","author":"Shakoor","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/ard.2005.042416_bib42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study","volume":"125","author":"Vermeire","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1136\/ard.2005.042416_bib43","first-page":"2287","article-title":"Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series","volume":"30","author":"Jarrett","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2005.042416_bib44","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/rheumatology\/41.1.116","article-title":"Etanercept and infliximab associated with cutaneous vasculitis","volume":"41","author":"McCain","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2005.042416_bib45","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/ndt\/gfh832","article-title":"Development of glomerulonephritis during anti-TNF-{alpha} therapy for rheumatoid arthritis","volume":"20","author":"Stokes","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1136\/ard.2005.042416_bib46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5414\/CNP62234","article-title":"Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis","volume":"62","author":"Doulton","year":"2004","journal-title":"Clin Nephrol"},{"key":"10.1136\/ard.2005.042416_bib47","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.4049\/jimmunol.167.12.6821","article-title":"In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL","volume":"167","author":"Via","year":"2001","journal-title":"J Immunol"},{"key":"10.1136\/ard.2005.042416_bib48","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1002\/art.20617","article-title":"Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide","volume":"50","author":"Bingham","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.042416_bib49","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/art.1780360812","article-title":"Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus","volume":"36","author":"Aderka","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2005.042416_bib50","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/rheumatology\/33.5.428","article-title":"Elevated serum levels of TNF soluble receptors in patients with positive anti-neutrophil cytoplasmic antibodies","volume":"33","author":"Roux-Lombard","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2005.042416_bib51","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMp048338","article-title":"The spectrum of Wegener's granulomatosis and disease relapse","volume":"352","author":"Bacon","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2005.042416_bib52","first-page":"161","article-title":"Classical versus non-renal Wegener's granulomatosis","volume":"87","author":"Luqmani","year":"1994","journal-title":"Q J Med"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724424850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724424850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2005.042416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:05:15Z","timestamp":1736139915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724424850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":52,"alternative-id":["S0003496724424850"],"URL":"https:\/\/doi.org\/10.1136\/ard.2005.042416","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[2005,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current state of tumour necrosis factor \u03b1 blockade in Wegener's granulomatosis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2005.042416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Copyright 2005 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}